Phase II and pharmacodynamic study of the farnesyltransferase inhibitor R115777 as initial therapy in patients with metastatic pancreatic adenocarcinoma.
暂无分享,去创建一个
Hao Wang | J. Pérez-Ruixo | L. Weiner | J. Abbruzzese | G. Hudes | J. Wright | Steven J. Cohen | R. Alpaugh | N. Meropol | N. Lewis | T. Verhaeghe | A. Rogatko | S. Ranganathan | M. Beard | S. Mclaughlin | L. Ho | Amanda M. Thistle | S. Cohen | S. McLaughlin
[1] R. Marks,et al. Phase II study of the farnesyl transferase inhibitor R115777 in patients with advanced non-small-cell lung cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] Daniel G Haller,et al. Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] J. Schellens,et al. Phase I clinical and pharmacologic study of chronic oral administration of the farnesyl protein transferase inhibitor R115777 in advanced cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] C. Rosty,et al. Molecular pathogenesis of pancreatic cancer. , 2002, Hematology/oncology clinics of North America.
[5] Steven J. Cohen,et al. Drug development in pancreatic cancer , 2002, International journal of gastrointestinal cancer.
[6] Ahmedin Jemal,et al. Cancer Statistics, 2002 , 2002, CA: a cancer journal for clinicians.
[7] J. Karp,et al. Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial. , 2001, Blood.
[8] C. Bowden,et al. Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro. , 2001, Cancer research.
[9] S. Sebti,et al. Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: Lessons from mechanism and bench-to-bedside translational studies , 2000, Oncogene.
[10] C. Bowden,et al. Phase I and pharmacokinetic study of farnesyl protein transferase inhibitor R115777 in advanced cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] Steven J. Cohen,et al. Pancreatic cancer , 2000, Current treatment options in oncology.
[12] M. Talamini,et al. Six hundred fifty consecutive pancreaticoduodenectomies in the 1990s: pathology, complications, and outcomes. , 1997, Annals of surgery.
[13] D. V. Von Hoff,et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] S. Sebti,et al. Inhibition of the prenylation of K-Ras, but not H- or N-Ras, is highly resistant to CAAX peptidomimetics and requires both a farnesyltransferase and a geranylgeranyltransferase I inhibitor in human tumor cell lines , 1997, Oncogene.
[15] S. Litwin,et al. Phase II studies: which is worse, false positive or false negative? , 1996, Journal of the National Cancer Institute.
[16] Schnall Sf,et al. Chemotherapy of adenocarcinoma of the pancreas. , 1996 .
[17] N. Rosen,et al. A peptidomimetic inhibitor of farnesyl:protein transferase blocks the anchorage-dependent and -independent growth of human tumor cell lines. , 1995, Cancer research.
[18] C. Bartram,et al. High frequency of Ki‐ras codon 12 mutations in pancreatic adenocarcinomas , 1989, International journal of cancer.
[19] A. Miller,et al. Reporting results of cancer treatment , 1981, Cancer.
[20] E. Kaplan,et al. Nonparametric Estimation from Incomplete Observations , 1958 .